Dr. Upadhyay is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
505 Parnassus Ave
San Francisco, CA 94143Phone+1 415-476-1528
Summary
- Dr. Vaibhav Upadhyay is an Assistant Professor in Pulmonary and Critical Care at UCSF. He received his medical degree from University of Chicago Division of the Biological Sciences The Pritzker School of Medicine. He specializes in critical care medicine. He is a physician scientist whose published works can be viewed here: https://www.ncbi.nlm.nih.gov/myncbi/1vKTAkd3asb5k/bibliography/public/
Education & Training
- University of California (San Francisco)Fellowship, Pulmonary Disease and Critical Care Medicine, 2018 - 2021
- University of California (San Francisco)Residency, Internal Medicine, 2015 - 2018
- University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 2015
Certifications & Licensure
- CA State Medical License 2016 - 2026
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Critical Care Medicine
- American Board of Internal Medicine Pulmonary Disease
Publications & Presentations
PubMed
- 2 citationsA diet-dependent host metabolite shapes the gut microbiota to protect from autoimmunity.Margaret Alexander, Vaibhav Upadhyay, Rachel Rock, Lorenzo Ramirez, Kai Trepka
Cell Reports. 2024-11-26 - Expansion of a bacterial operon during cancer treatment ameliorates drug toxicity.Kai R Trepka, Wesley A Kidder, Than S Kyaw, Taylor Halsey, Christine A Olson
Biorxiv. 2024-10-15 - 2 citationsPhage Immunoprecipitation-Sequencing Reveals CDHR5 Autoantibodies in Select Patients With Interstitial Lung Disease.Vaibhav Upadhyay, Young Me Yoon, Sara E Vazquez, Tania E Velez, Kirk D Jones
ACR Open Rheumatology. 2024-09-01
Press Mentions
- CDC Rates Pfizer Vaccine 66% on Efficacy Scale Against Delta VariantOctober 4th, 2021
- How COVID-19 Variants Could Outsmart VaccinesSeptember 28th, 2021
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: